

DAFTAR PUSTAKA

- Akagi, T., Benson, L.N., Lightfoot, N.E., Chin, K., Wilson, G., Freedom, R.M. 1991. Natural history of dilated cardiomyopathy in children. *Am Heart J*, 121(5): 1502–1506.
- de Albuquerque Suassuna, P.G., Sanders-Pinheiro, H., de Paula, R.B. 2018. Uremic cardiomyopathy: A new piece in the chronic kidney disease-mineral and bone disorder puzzle. *Front Med*, 5: 1–10.
- Alvarez, J.A., Wilkinson, J.D., Lipshultz, S.E. 2007. Outcome predictors for pediatric dilated cardiomyopathy: A systematic review. *Prog Pediatr Cardiol*, 23(1–2): 25–32.
- Ari, M.E., Yoldas, T., Örün, U.A., Karademir, S. 2019. Idiopathic dilated cardiomyopathy in children: Prognostic indicators. *Turk Kardiyol Dern Ars*, 47(3): 207–215.
- Azevedo, V.M.P., Filho, F.M.A., Santos, M.A., Castier, M.B., Tura, B.R. 2004. Prognostic value of chest roentgenograms in children with idiopathic dilated cardiomyopathy. *J Pediatr (Rio J)*, 80(1): 71–6.
- Bellinger, A.M., Arteaga, C.L., Force, T., Humphreys, B.D., Demetri, G.D., Druker, B.J., Moslehi, J.J. 2015. Cardio-oncology: How new targeted cancer therapies and precision medicine can inform cardiovascular discovery. *Circulation*, 132(23): 2248–2258.
- Bostan, Ö.M., Cil, E. 2006. Dilated cardiomyopathy in childhood: Prognostic features and outcome. *Acta Cardiol*, 61(2): 169–72.
- Cabrerizo, M., Díaz-Cerio, M., Muñoz-Almagro, C., Rabella, N., Tarragó, D., Romero, M.P., et al. 2017. Molecular epidemiology of enterovirus and parechovirus infections according to patient age over a 4-year period in Spain. *J Med Virol*, 89: 435–442.
- Caforio, A.L.P., Pankuweit, S., Arbustini, E., Basso, C., Gimeno-Blanes, J., Felix, S.B., et.al. 2013. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J*, 34: 2636–2648.
- Cardinale, D., Colombo, A., Sandri, M.T., Lamantia, G., Colombo, N., Civelli, M., Martinelli, G., et al. 2006. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. *Circulation*, 114: 2474–2481.
- Carvalho, J.S., Silva, C.M.C., Shinebourne, E.A., Redington, A.N. 1996. Prognostic value of posterior wall thickness in childhood dilated cardiomyopathy and myocarditis. *Eur Heart J*, 17: 1233–1238.

- Castelli, G., Fornaro, A., Ciaccheri, M., Dolara, A., Troiani, V., Tomberli, B., et al. 2013. Improving survival rates of patients with idiopathic dilated cardiomyopathy in tuscany over 3 decades: Impact of evidence-based management. *Circ Hear Fail*, 6: 913–921.
- Chatterjee, K., Zhang, J., Honbo, N., Karliner, J.S. 2010. Doxorubicin cardiomyopathy. *Cardiology*, 115: 155–162.
- Chen, S.C., Nouri, S., Balfour, I., Jureidini, S., Appleton, R.S. 1990. Clinical profile of congestive cardiomyopathy in children. *J Am Coll Cardiol*, 15(1): 189–193.
- Daubeney, Piers E.F., Nugent, A.W., Chondros, P., Carlin, J.B., Colan, S.D., et al. 2006. Clinical features and outcomes of childhood dilated cardiomyopathy: Results from a national population-based study. *Circulation*, 114(24): 2671–2678.
- Daubeney, Piers E. F., Nugent, A.W., Chondros, P., Carlin, J.B., Colan, S.D., et al. 2006. Clinical Features and Outcomes of Childhood Dilated Cardiomyopathy. *Circulation*, 114(24): 2671–2678.
- Dec, G.W., Fuster, V. 1994. Idiopathic Dilated Cardiomyopathy. *N Engl J Med*, (331): 1564–1575.
- Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J.J.V. 2008. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart. *Eur J Heart Fail*, 10(10): 933–989.
- Ehlert, F.A., Cannom, D.S., Renfroe, E.G., Greene, H.L., Ledingham, R., Mitchell, L.B., et al. 2001. Comparison of dilated cardiomyopathy and coronary artery disease in patients with life-threatening ventricular arrhythmias: Differences in presentation and outcome in the AVID registry. *Am Heart J*, 142(5): 816–822.
- Fadl, S., Wåhlander, H., Fall, K., Cao, Y., Sunnegårdh, J. 2018. The highest mortality rates in childhood dilated cardiomyopathy occur during the first year after diagnosis. *Acta Paediatr Int J Paediatr*, 107: pp 672–677.
- Faid, T. 2021. Dilated Cardiomyopathy in Systemic Lupus Erythematosus : A Pediatric Case Report. , 28: 1–11.
- Fatkin, D., Otway, R., Richmond, Z. 2010. Genetics of Dilated Cardiomyopathy. *Heart Fail Clin*, 6(2): 129–140. <http://dx.doi.org/10.1016/j.hfc.2009.11.003>.
- Griffin, M L, Hernandez, a, Martin, T.C., Goldring, D., Bolman, R.M., Spray, T.L., Strauss, a W. 1988. Dilated cardiomyopathy in infants and children. *J Am Coll Cardiol*, 11(1): 139–144.
- Griffin, Michael L., Hernandez, A., Martin, T.C., Goldring, D., Bolman, R.M., Spray, T.L., Strauss, A.W. 1988. Dilated cardiomyopathy in infants and children. *J Am Coll Cardiol*, 11(1): 139–144.
- Groner, A., Yau, J., Lytrivi, I.D., Ko, H.H., Nielsen, J.C., Parness, I.A., Srivastava, S. 2013. The role of right ventricular function in paediatric idiopathic dilated cardiomyopathy. *Cardiol Young*, 23(3): 409–415.

- Guevara, J.P., Clark, B.J., Athreya, B.H. 2001. Point prevalence of cardiac abnormalities in children with systemic lupus erythematosus. *J Rheumatol*, 28(4): 854–859.
- Halliday, B.P., Gulati, A., Ali, A., Newsome, S., Lota, A., Tayal, U., et al. 2018. Sex- and age-based differences in the natural history and outcome of dilated cardiomyopathy. *Eur J Heart Fail*, 20: 1392–1400.
- Kliegman, R.M., Geme, J.W., Blum N.J, Shah S.S, Tasker R.C., W.K.M. 2019. *Nelson Textbook of Pediatrics*. 21st ed. Philadelphia: Elsevier.
- Lancellotti, P., Tribouilloy, C., Hagendorff, A., Popescu, B.A., Edvardsen, T., Pierard, L.A., et al. 2013. Recommendations for the echocardiographic assessment of native valvular regurgitation: An executive summary from the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*, 14(7): 611–644.
- Lee, T.M., Hsu, D.T., Kantor, P., Towbin, J.A., Ware, S.M., Colan, S.D., et al. 2017. Pediatric cardiomyopathies. *Circ Res*, 121(7): 855–873.
- Lipshultz, S.E., S. et al. 2003. The Incidence of Pediatric Cardiomyopathy in Two Regions of the United States. *N Engl J Med*, 348: 1647–55.
- Lipshultz, S.E., Adams, M.J., Colan, S.D., Constine, L.S., Herman, E.H., Hsu, D.T., et al. 2013. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: Pathophysiology, course, monitoring, management, prevention, and research directions: A scientific statement from the American Heart Association. *Circulation*, 128(17): 1927–1955.
- Lipshultz, S.E., Law, Y.M., Asante-Korang, A., Austin, E.D., Dipchand, A.I., Everitt, M.D., et al. 2019. Cardiomyopathy in Children: Classification and Diagnosis: A Scientific Statement From the American Heart Association. *Circulation*, 140(1): E9–E68.
- Lipshultz, S.E., Lipsitz, S.R., Sallan, S.E., Dalton, V.M., Mone, S.M., Gelber, R.D., et al. 2005. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. *J Clin Oncol*, 23(12): 2629–2636.
- Lozano, R., et al. 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. *Lancet*, 380: 2095–2128.
- Maganti, K., Rigolin, V.H., Sarano, M.E., Bonow, R.O. 2010. Valvular heart disease: Diagnosis and management. *Mayo Clin Proc*, 85(5): 483–500.
- Mathew, T., Williams, L., Navaratnam, G., Rana, B., Wheeler, R., Collins, K., et al. 2017. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. *Echo Res Pract*, 16–0037: G1–G13.
- Matitiau, A., Perez-Atayde, A., Sanders, S.P., Sluysmans, T., Parness, I.A., Spevak, P.J., Colan, S.D. 1994. Infantile dilated cardiomyopathy: Relation of outcome to left ventricular mechanics, hemodynamics, and histology at the time of

- presentation. *Circulation*, 90(3): 1310–1318.
- Matsumori, A., Shimada, T., Chapman, N.M., Tracy, S.M., Mason, J.W. 2006. Myocarditis and Heart Failure Associated With Hepatitis C Virus Infection. *J Card Fail*, 92(9): 2519–2525.
- McLaughlin, E.S., Travers, C., Border, W.L., Deshpande, S., Sachdeva, R. 2017. Tricuspid annular plane systolic excursion as a marker of right ventricular dysfunction in pediatric patients with dilated cardiomyopathy. *Echocardiography*, 34(1): 102–107.
- Mestroni, L., Maisch, B., McKenna, W.J., Schwartz, K., Charron, P., Rocco, C., Tesson, F., Richter, A., Wilke, A., Komajda, M. 1999. Guidelines for the study of familial dilated cardiomyopathies. *Eur Heart J*, 20(2): 93–102.
- Molina, K.M., Shrader, P., Colan, S.D., Mital, S., Margossian, R., Sleeper, L.A., et al. 2013. Predictors of disease progression in pediatric dilated cardiomyopathy. *Circ Hear Fail*, 6(6): 1214–1222.
- Nugent, A.W., Daubeney, P.E., Chondros, P., Carlin, J.B., Cheung, M., Wilkinson, L.C., et al. 2003. The Epidemiology of Childhood Cardiomyopathy in Australia. *n engl j med*, 348(17): 1639–1685. www.nejm.org.
- O’Connell, J.B., Bristow, M.R. 1994. Economic impact of heart failure in the United States: Time for a different approach. *J Hear Lung Transplant*, 13(4): S107-12.
- Öztunç, F., Babaoğlu, K., Yilmaz, E., Demir, T., Ahunbay, G. 2007. Predictive value of cardiothoracic ratio as a marker of severity of aortic regurgitation and mitral regurgitation. *Anadolu Kardiyol Derg*, 7: 146–9.
- Park, M.K. 2008. Dilated or Congestive Cardiomyopathy. In *Pediatric cardiology for Practitioners*. 321–338.
- Patange, A., Thomas, R., Ross, R.D. 2013. Severity of Mitral Regurgitation Predicts Risk of Death or Cardiac Transplantation in Children With Idiopathic Dilated Cardiomyopathy. *Pediatr Cardiol* 2013 352, 35(2): 232–238. <https://link.springer.com/article/10.1007/s00246-013-0764-7> 8 September 2021.
- Rahayuningsih, S.E. 2016. Manifestasi Klinis dan Fungsi Ventrikel pada Kardiomiopati Dilatasi. *Sari Pediatr*, 16(6): 403.
- Sabaz, M.N., Akın, A., Bilici, M., Demir, F., Türe, M., Balık, H. 2019. Factors affecting mortality in children with dilated cardiomyopathy. *Turk J Pediatr*, 61(4): 485–492.
- Sastroasmoro, S. 2020. *Kardiologi anak : buku ajar*. Ikatan Dokter Anak Indonesia.
- Sastroasmoro, S. 1994. *Kardiologi anak : buku ajar*. In *Buku Ajar Kardiologi anak*. Ikatan Dokter Anak Indonesia: 317–323.
- Taliencio, C.P., Seward, J.B., Driscoll, D.J., Fisher, L.D., Gersh, B.J., Tajik, A.J. 1985. Idiopathic dilated cardiomyopathy in the young: Clinical profile and natural history. *J Am Coll Cardiol*, 6(5): 1126–1131. [http://dx.doi.org/10.1016/S0735-1097\(85\)80319-3](http://dx.doi.org/10.1016/S0735-1097(85)80319-3).



- Towbin, J. a, Lowe, A.M., Colan, S.D., Sleeper, L. a, Orav, E.J., Clunie, S., et al. 2006. of Dilated Cardiomyopathy in Children. *JAMA*, 296(15): 1867–76. <http://www.ncbi.nlm.nih.gov/pubmed/17047217>.
- Towbin, J.A., Lowe, A.M., Colan, S.D., Sleeper, L.A., Orav, E.J., Clunie, S., et al. 2006. Incidence, causes, and outcomes of dilated cardiomyopathy in children. *J Am Med Assoc*, 296(15): 1867–1876.
- Türe, M., Balık, H., Akın, A., Bilici, M., Nergiz, A. 2020. The relationship between electrocardiographic data and mortality in children diagnosed with dilated cardiomyopathy. *Eur J Pediatr*, 179(5): 813–819.
- Venugopalan, P., Houston, A.B., Agarwal, A.K. 2001. The outcome of idiopathic dilated cardiomyopathy and myocarditis in children from the west of Scotland. *Int J Cardiol*, 78(2): P135-141.
- Weng, K.P., Lin, C.C., Huang, S.H., Hsieh, K.S. 2005. Idiopathic dilated cardiomyopathy in children. A single medical center's experience. *J Chinese Med Assoc*, 68(8): 368–372. [http://dx.doi.org/10.1016/S1726-4901\(09\)70177-7](http://dx.doi.org/10.1016/S1726-4901(09)70177-7).
- Wiles, H.B., McArthur, P.D., Taylor, A.B., Gillette, P.C., Fyfe, D.A., Matthews, J.P., Shelton, L.W. 1991. Prognostic features of children with idiopathic dilated cardiomyopathy. *Am J Cardiol*, 68(13): P1372-1376.
- Wilkinson, J.D., Westphal, J.A., Bansal, N., Czachor, J.D., Razoky, H., Lipshultz, S.E. 2015. Lessons learned from the Pediatric Cardiomyopathy Registry (PCMR) Study Group*. *Cardiol Young*, 25(2): 140–153. <https://doi.org/10.1017/S1047951115000943>.
- William. 2014. Patofisiologi dan Patogenenis Kardiomiopati. *J Kedokt Meditek*, 20(52): 19–27.
- Yeantesa, P., Karani, Y. 2018. Etiologi dan Patofisiologi Kardiomiopati Dilatasi. *J Kesehatan Andalas*, 7: 135–143.